We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

NanoKTN Supports Regenerative Medicine Development

Read time: 1 minute

The Nanotechnology Knowledge Transfer Network (NanoKTN) has announced its support to a consortium led by the MRC Centre for Drug Safety Science, University of Liverpool, which has been awarded £4.5M for a UK Regenerative Medicine Platform (UKRMP) Safety Hub.
 
The Hub aims to develop methods to monitor the biodistribution and behaviour of transplanted cells in well-characterised disease models, using innovative nanochemistry and molecular imaging, and brings together experts in nanochemistry, imaging, stem cell biology and safety science, to enable clinical translation of safe, effective regenerative medicine therapies.
 
Following the successful launch of the UKRMP Safety Hub, the NanoKTN will now be supporting them with future networking activities and events to help to disseminate the outcomes from their work and to increase links to the business community.
 
The NanoKTN supports the transfer of knowledge and experience between key research organisations, in order to develop new strategies and clinical imaging protocols necessary for effective safety assessment of regenerative medicine therapies. These developments are imperative to enable the clinical adoption of such therapies and to ensure that the UK realises its potential as its regenerative medicine industry develops.
 
Dr Felicity Sartain, Theme Manager - Healthcare and Life Sciences at the NanoKTN explains, “One of the key areas within the NanoKTN’s Healthcare and Life Sciences theme is nanomedicine, and this application can only be successfully developed into treatments if clinicians and healthcare professionals engage with the life science industry. The NanoKTN will be working with the University of Liverpool to disseminate information and outcomes from the UKRMP Safety Hub, through networking activities, co-organised events and providing representation on the steering committee.”
 
Dr Sartain continues, “The link between academic research and industry is already close in the life sciences industries and we are looking forward to bringing these communities even closer together to help the UKRMP Safety Hub develop its plans and help to identify companies for future collaboration through our industry network of UK members.”